{"success":true,"data":{"pressRelease":{"id":"51854","rtpr_id":"nGNX9vhf20","ticker":"OCUL","exchange":"NASDAQ","all_tickers":["OCUL"],"title":"Ocular Therapeutix™ to Host Investor Day on June 17, 2026","author":"Globe Newswire","published_at":"2026-06-02T11:00:00.360Z","article_body":"In addition to Ocular leadership, event to feature prominent retinal disease\nexperts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS;\nand Dr. Darius M. Moshfeghi, MD \n\nCompany to highlight AXPAXLI™ wet AMD NDA submission plan, updates on SOL-R,\nSOL-X, and registrational diabetic retinopathy program, and an overview of the\nplanned commercialization approach for AXPAXLI, if approved\n\nThe live event will take place in New York City on June 17, 2026, starting at\n2:00 PM ET\n\nBEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.\n(NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company\ncommitted to redefining the retina experience, will host an Investor Day on\nWednesday, June 17, 2026, in New York City. Click here\n(https://www.globenewswire.com/Tracker?data=6ILWGh5TZrHQY0LHY2W7asM0pzNuwXdcPPfNFvJAAGnimWSnDIl88kB6yRacBrU8vuJ9D-EoXUztM70i8BDuOcQAy2X1bZFrDnl1aHlm4Mw=)\nto register for the live event, with virtual access available, which will\nbegin at 2:00 PM ET. \n\nThe Investor Day will include presentations from Ocular’s senior leadership\nand roundtable discussions with prominent retinal disease Key Opinion Leaders\n(KOLs), followed by a live Q&A session. In-person attendees are invited to\njoin Ocular’s leadership team for a networking reception to conclude the\nevent.\n\nThe prominent retinal disease KOLs participating in Ocular’s Investor Day\ninclude:\n* Dr. Arshad M. Khanani, MD, MA, FASRS: Managing Partner, Director of Clinical\nResearch and Director of Fellowship, Sierra Eye Associates; Clinical\nProfessor, University of Nevada, Reno School of Medicine.\n* Dr. Lejla Vajzovic, MD, FASRS: Professor of Ophthalmology at Duke University\nSchool of Medicine.\n* Dr. Darius M. Moshfeghi, MD: Chief of the Retina Division at Byers Eye\nInstitute of Stanford University School of Medicine.\nPresentations from Company leadership and KOL discussions will focus on\nregulatory updates regarding the NDA submission plan for AXPAXLI in wet AMD; a\nreview of the ongoing SOL-R and SOL-X trials in wet AMD; an update on the\nregistrational program for AXPAXLI in diabetic retinopathy; and an overview of\nthe planned commercialization strategy for AXPAXLI in wet AMD, if approved. \n\nA live webcast of the presentation will be available on the “Events and\nPresentations” section of the Company’s website. A replay of the webcast\nwill be archived and available to be viewed for at least 30 days following the\npresentation.\n\nAbout Dr. Arshad M. Khanani\nArshad M. Khanani, MD, MA, FASRS, is the Managing Partner, Director of\nClinical Research, and Director of Fellowship at Sierra Eye Associates, as\nwell as a Clinical Professor at the University of Nevada, Reno School of\nMedicine.\n\nDr. Khanani founded the clinical research department at Sierra Eye Associates,\nwhich has since become one of the nation's leading centers for clinical\nresearch. He has served as the principal investigator in over 150 clinical\ntrials and has been a top enroller for several Phase 1-3 trials. He is also at\nthe forefront of several collaborative studies examining real-world outcomes\nfor newly approved treatments. Additionally, Dr. Khanani was the first to\nperform surgical procedures in various clinical trials focused on sustained\ndrug delivery and gene therapy. His extensive body of work includes numerous\npublications in highly regarded journals such as The Lancet, Ophthalmology,\nand JAMA Ophthalmology.\n\nDr. Khanani is a lead principal investigator for several ongoing clinical\ntrials and contributes to national and international clinical trial steering\ncommittees and scientific advisory boards. These efforts are aimed at\ndeveloping new treatment options for patients with retinal diseases. A\nsought-after speaker, he is frequently invited to present at major national\nand international meetings. In 2021, Dr. Khanani founded the Clinical Trials\nat the Summit meeting to foster discussion on clinical trial design and data.\nDr. Khanani is a distinguished member of both the Macula Society and\nthe Retina Society and has received numerous prestigious honors throughout\nhis career. These include the Lawrence J. Singerman Medal from the Macula\nSociety in 2025, recognizing his outstanding contributions to advancing\nretinal science through clinical trials; the Presidential Award from\nthe American Society of Retina Specialists (ASRS) in 2024; and the ASRS\nPresidents Young Investigator Award in 2021. In addition, Dr. Khanani was\nrecognized as one of the world’s Top 10 ophthalmology researchers in The\nOphthalmologist Power List 2025.\n\nAbout Dr. Lejla Vajzovic, MD\nLejla Vajzovic, MD, FASRS, is a vitreoretinal surgeon, clinician-scientist,\neducator, and internationally recognized leader in retinal disease, surgical\ninnovation, and regenerative vision therapies. She is a tenured Professor of\nOphthalmology, Pediatrics, and Biomedical Engineering at Duke University,\nDirector of the Duke Vitreoretinal Surgical Fellowship Program, Co-Director of\nthe Duke Pediatric Retina and Optic Nerve Center, and Director of the Duke Eye\nCenter's Continuing Medical Education Program.\n\nDr. Vajzovic is recognized worldwide for her expertise in adult and pediatric\nvitreoretinal surgery, inherited retinal diseases, gene therapy, advanced\nretinal imaging, artificial intelligence, and novel surgical technologies. Her\nclinical and research efforts have advanced the care of patients with common\nretinal diseases, including age-related macular degeneration and diabetic\nretinopathy, as well as rare and complex retinal disorders such as inherited\nretinal degenerations, retinopathy of prematurity, pediatric retinal\ndetachments, retinoblastoma, and Coats disease.\n\nAn internationally respected clinician-scientist, Dr. Vajzovic has served as\nprincipal investigator and scientific advisor for numerous national and\ninternational clinical trials evaluating gene therapies, regenerative\ntherapies, artificial intelligence applications, and novel treatments for\nblinding retinal diseases. She is a sought-after speaker at major ophthalmic\nmeetings worldwide and has helped shape the future of retinal care through her\ncontributions to clinical research, surgical innovation, and medical\neducation.\n\nA passionate educator and mentor, Dr. Vajzovic directs the prestigious Duke\nVitreoretinal Surgical Fellowship and leads several nationally and\ninternationally recognized educational programs, including the Duke Fellows\nAdvances in Vitreous Surgery Course and the Advances in Pediatric Retina\nCourse. She has trained and mentored numerous future leaders in ophthalmology\nand considers the success of her trainees to be her greatest professional\naccomplishment.\n\nDr. Vajzovic is an elected member of the Retina Society, the Macula Society,\nand the Club Jules Gonin. She currently serves as President-Elect of Women in\nOphthalmology and will assume the presidency in 2027. Her contributions have\nbeen recognized with numerous honors, including the American Academy of\nOphthalmology Achievement Award, the American Society of Retina Specialists\nSenior Honor Award, the Women in Ophthalmology Emerging Leader Award, the Duke\nUniversity School of Medicine Emerging Leader Award, the Duke Medical Alumni\nAssociation Emerging Leader Award, the Vit-Buckle Society Mentorship Award,\nand the Real World Ophthalmology Extraordinary Mentorship Award.\n\nThrough her leadership in patient care, research, education, and mentorship,\nDr. Vajzovic continues to advance the field of retina and improve the lives of\npatients with vision-threatening diseases around the world.\n\nAbout Darius M. Moshfeghi, MD\nDarius M. Moshfeghi, MD, is Professor and Chief of Retina at the Byers Eye\nInstitute at the Stanford University School of Medicine where he established\nthe vitreoretinal fellowship program in 2009. He is internationally recognized\nfor his pioneering work to promote telemedicine for the prevention of\nblindness in premature and term infants, establishing the Stanford University\nNetwork for the Diagnosis of Retinopathy of Prematurity (SUNDROP) \nnetwork in 2005 which has expanded with a collaboration with Pediatrix to\nprovide ROP screening coverage for 2.5% of USA neonatal intensive care units\nand >4% of eligible infants.\n\nSince 2024, he has been the Senior grader at the Zero Blind Babies program to\neradicate ROP blindness in Sub Saharan Africa using telemedicine with local\ngrades and quaternary Stanford graders, the largest telemedicine program in\nAfrica.\n\nHis entrepreneurial work centers around telemedicine applications in eye\nhealth, and he is currently the Chief Medical Advisor at Vision Labs Inc,\nwhich has created a platform mobile keratometry system. He founded and was\nChairman of Placid0 until its acquisition by Waldo, Inc., in November of 2021,\nserved on the Board of directors of 1-800 Contacts until its acquisition by\nKKR in November of 2020. Dr. Moshfeghi teamed with Dr. Jochen Kumm to form\nPr3vent in 2017 to implement universal newborn eye screening for retinal and\nocular abnormalities in healthy newborn infants.\n\nHe has served on the Collaborative Community on Ophthalmic Imaging for ROP\nSection, the American Academy of Ophthalmology Telemedicine Working Group and\nAAO ROP Telemedicine Task Force Panel.\n\nCurrently, he leads the advisory board for Feliqs for their ROP prevention\nstrategy which is in a Phase 1 trial in the United States. He led the steering\ncommittee for the Regeneron BUTTERFLEYE trial and the photographic imaging\ncommittee for Bayer FIREFLEYE trial of aflibercept for ROP.\n\nHe is active in Data Monitoring Safety Boards working with Affamed, Alcon,\nIcon Clinical Research, Insite DME, Novartis, and Vanotech Chengdu.\n\nDr. Moshfeghi was inducted into the 2021 class of the Retina Hall of Fame and\nis a member of the Club Jules Gonin, Retina Society, Macula Society, American\nSociety of Retinal Specialists, and the Association of Pediatric Retinal\nSpecialists.\n\nAbout Ocular Therapeutix, Inc.\nOcular Therapeutix, Inc. is an integrated biopharmaceutical company committed\nto redefining the retina experience. AXPAXLI™ (also known as OTX-TKI),\nOcular’s investigational product candidate for retinal disease, is an\naxitinib intravitreal hydrogel based on its ELUTYX™ proprietary\nbioresorbable hydrogel-based formulation technology. AXPAXLI is currently in\nPhase 3 clinical trials for wet age-related macular degeneration (wet AMD),\nand diabetic retinal disease, including non-proliferative diabetic retinopathy\n(NPDR).\n\nOcular’s pipeline also leverages the ELUTYX technology in its commercial\nproduct DEXTENZA(®), an FDA-approved corticosteroid for the treatment of\nocular inflammation and pain following ophthalmic surgery in adults and\npediatric patients and ocular itching associated with allergic conjunctivitis\nin adults and pediatric patients aged two years or older, and in its\ninvestigational product candidate OTX-TIC, which is a travoprost intracameral\nhydrogel that has completed a Phase 2 clinical trial for the treatment of\nopen-angle glaucoma or ocular hypertension. Ocular is currently evaluating\nnext steps for the OTX-TIC program.\n\nFollow the Company on its website, LinkedIn, or X.\n\nDEXTENZA(®) is a registered trademark of Ocular Therapeutix, Inc. The Ocular\nTherapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are\ntrademarks of Ocular Therapeutix, Inc.\n\nInvestors & Media\nOcular Therapeutix, Inc.\nBill Slattery\nVice President, Investor Relations\nbslattery@ocutx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/20ee0f50-7288-4f81-8546-f2ad2050ddbf)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9vhf20","title":"Ocular Therapeutix™ to Host Investor Day on June 17, 2026","author":"Globe Newswire","ticker":"OCUL","created":"2026-06-02T11:00:00.360Z","tickers":["OCUL"],"exchange":"NASDAQ","article_body":"In addition to Ocular leadership, event to feature prominent retinal disease\nexperts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS;\nand Dr. Darius M. Moshfeghi, MD \n\nCompany to highlight AXPAXLI™ wet AMD NDA submission plan, updates on SOL-R,\nSOL-X, and registrational diabetic retinopathy program, and an overview of the\nplanned commercialization approach for AXPAXLI, if approved\n\nThe live event will take place in New York City on June 17, 2026, starting at\n2:00 PM ET\n\nBEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.\n(NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company\ncommitted to redefining the retina experience, will host an Investor Day on\nWednesday, June 17, 2026, in New York City. Click here\n(https://www.globenewswire.com/Tracker?data=6ILWGh5TZrHQY0LHY2W7asM0pzNuwXdcPPfNFvJAAGnimWSnDIl88kB6yRacBrU8vuJ9D-EoXUztM70i8BDuOcQAy2X1bZFrDnl1aHlm4Mw=)\nto register for the live event, with virtual access available, which will\nbegin at 2:00 PM ET. \n\nThe Investor Day will include presentations from Ocular’s senior leadership\nand roundtable discussions with prominent retinal disease Key Opinion Leaders\n(KOLs), followed by a live Q&A session. In-person attendees are invited to\njoin Ocular’s leadership team for a networking reception to conclude the\nevent.\n\nThe prominent retinal disease KOLs participating in Ocular’s Investor Day\ninclude:\n* Dr. Arshad M. Khanani, MD, MA, FASRS: Managing Partner, Director of Clinical\nResearch and Director of Fellowship, Sierra Eye Associates; Clinical\nProfessor, University of Nevada, Reno School of Medicine.\n* Dr. Lejla Vajzovic, MD, FASRS: Professor of Ophthalmology at Duke University\nSchool of Medicine.\n* Dr. Darius M. Moshfeghi, MD: Chief of the Retina Division at Byers Eye\nInstitute of Stanford University School of Medicine.\nPresentations from Company leadership and KOL discussions will focus on\nregulatory updates regarding the NDA submission plan for AXPAXLI in wet AMD; a\nreview of the ongoing SOL-R and SOL-X trials in wet AMD; an update on the\nregistrational program for AXPAXLI in diabetic retinopathy; and an overview of\nthe planned commercialization strategy for AXPAXLI in wet AMD, if approved. \n\nA live webcast of the presentation will be available on the “Events and\nPresentations” section of the Company’s website. A replay of the webcast\nwill be archived and available to be viewed for at least 30 days following the\npresentation.\n\nAbout Dr. Arshad M. Khanani\nArshad M. Khanani, MD, MA, FASRS, is the Managing Partner, Director of\nClinical Research, and Director of Fellowship at Sierra Eye Associates, as\nwell as a Clinical Professor at the University of Nevada, Reno School of\nMedicine.\n\nDr. Khanani founded the clinical research department at Sierra Eye Associates,\nwhich has since become one of the nation's leading centers for clinical\nresearch. He has served as the principal investigator in over 150 clinical\ntrials and has been a top enroller for several Phase 1-3 trials. He is also at\nthe forefront of several collaborative studies examining real-world outcomes\nfor newly approved treatments. Additionally, Dr. Khanani was the first to\nperform surgical procedures in various clinical trials focused on sustained\ndrug delivery and gene therapy. His extensive body of work includes numerous\npublications in highly regarded journals such as The Lancet, Ophthalmology,\nand JAMA Ophthalmology.\n\nDr. Khanani is a lead principal investigator for several ongoing clinical\ntrials and contributes to national and international clinical trial steering\ncommittees and scientific advisory boards. These efforts are aimed at\ndeveloping new treatment options for patients with retinal diseases. A\nsought-after speaker, he is frequently invited to present at major national\nand international meetings. In 2021, Dr. Khanani founded the Clinical Trials\nat the Summit meeting to foster discussion on clinical trial design and data.\nDr. Khanani is a distinguished member of both the Macula Society and\nthe Retina Society and has received numerous prestigious honors throughout\nhis career. These include the Lawrence J. Singerman Medal from the Macula\nSociety in 2025, recognizing his outstanding contributions to advancing\nretinal science through clinical trials; the Presidential Award from\nthe American Society of Retina Specialists (ASRS) in 2024; and the ASRS\nPresidents Young Investigator Award in 2021. In addition, Dr. Khanani was\nrecognized as one of the world’s Top 10 ophthalmology researchers in The\nOphthalmologist Power List 2025.\n\nAbout Dr. Lejla Vajzovic, MD\nLejla Vajzovic, MD, FASRS, is a vitreoretinal surgeon, clinician-scientist,\neducator, and internationally recognized leader in retinal disease, surgical\ninnovation, and regenerative vision therapies. She is a tenured Professor of\nOphthalmology, Pediatrics, and Biomedical Engineering at Duke University,\nDirector of the Duke Vitreoretinal Surgical Fellowship Program, Co-Director of\nthe Duke Pediatric Retina and Optic Nerve Center, and Director of the Duke Eye\nCenter's Continuing Medical Education Program.\n\nDr. Vajzovic is recognized worldwide for her expertise in adult and pediatric\nvitreoretinal surgery, inherited retinal diseases, gene therapy, advanced\nretinal imaging, artificial intelligence, and novel surgical technologies. Her\nclinical and research efforts have advanced the care of patients with common\nretinal diseases, including age-related macular degeneration and diabetic\nretinopathy, as well as rare and complex retinal disorders such as inherited\nretinal degenerations, retinopathy of prematurity, pediatric retinal\ndetachments, retinoblastoma, and Coats disease.\n\nAn internationally respected clinician-scientist, Dr. Vajzovic has served as\nprincipal investigator and scientific advisor for numerous national and\ninternational clinical trials evaluating gene therapies, regenerative\ntherapies, artificial intelligence applications, and novel treatments for\nblinding retinal diseases. She is a sought-after speaker at major ophthalmic\nmeetings worldwide and has helped shape the future of retinal care through her\ncontributions to clinical research, surgical innovation, and medical\neducation.\n\nA passionate educator and mentor, Dr. Vajzovic directs the prestigious Duke\nVitreoretinal Surgical Fellowship and leads several nationally and\ninternationally recognized educational programs, including the Duke Fellows\nAdvances in Vitreous Surgery Course and the Advances in Pediatric Retina\nCourse. She has trained and mentored numerous future leaders in ophthalmology\nand considers the success of her trainees to be her greatest professional\naccomplishment.\n\nDr. Vajzovic is an elected member of the Retina Society, the Macula Society,\nand the Club Jules Gonin. She currently serves as President-Elect of Women in\nOphthalmology and will assume the presidency in 2027. Her contributions have\nbeen recognized with numerous honors, including the American Academy of\nOphthalmology Achievement Award, the American Society of Retina Specialists\nSenior Honor Award, the Women in Ophthalmology Emerging Leader Award, the Duke\nUniversity School of Medicine Emerging Leader Award, the Duke Medical Alumni\nAssociation Emerging Leader Award, the Vit-Buckle Society Mentorship Award,\nand the Real World Ophthalmology Extraordinary Mentorship Award.\n\nThrough her leadership in patient care, research, education, and mentorship,\nDr. Vajzovic continues to advance the field of retina and improve the lives of\npatients with vision-threatening diseases around the world.\n\nAbout Darius M. Moshfeghi, MD\nDarius M. Moshfeghi, MD, is Professor and Chief of Retina at the Byers Eye\nInstitute at the Stanford University School of Medicine where he established\nthe vitreoretinal fellowship program in 2009. He is internationally recognized\nfor his pioneering work to promote telemedicine for the prevention of\nblindness in premature and term infants, establishing the Stanford University\nNetwork for the Diagnosis of Retinopathy of Prematurity (SUNDROP) \nnetwork in 2005 which has expanded with a collaboration with Pediatrix to\nprovide ROP screening coverage for 2.5% of USA neonatal intensive care units\nand >4% of eligible infants.\n\nSince 2024, he has been the Senior grader at the Zero Blind Babies program to\neradicate ROP blindness in Sub Saharan Africa using telemedicine with local\ngrades and quaternary Stanford graders, the largest telemedicine program in\nAfrica.\n\nHis entrepreneurial work centers around telemedicine applications in eye\nhealth, and he is currently the Chief Medical Advisor at Vision Labs Inc,\nwhich has created a platform mobile keratometry system. He founded and was\nChairman of Placid0 until its acquisition by Waldo, Inc., in November of 2021,\nserved on the Board of directors of 1-800 Contacts until its acquisition by\nKKR in November of 2020. Dr. Moshfeghi teamed with Dr. Jochen Kumm to form\nPr3vent in 2017 to implement universal newborn eye screening for retinal and\nocular abnormalities in healthy newborn infants.\n\nHe has served on the Collaborative Community on Ophthalmic Imaging for ROP\nSection, the American Academy of Ophthalmology Telemedicine Working Group and\nAAO ROP Telemedicine Task Force Panel.\n\nCurrently, he leads the advisory board for Feliqs for their ROP prevention\nstrategy which is in a Phase 1 trial in the United States. He led the steering\ncommittee for the Regeneron BUTTERFLEYE trial and the photographic imaging\ncommittee for Bayer FIREFLEYE trial of aflibercept for ROP.\n\nHe is active in Data Monitoring Safety Boards working with Affamed, Alcon,\nIcon Clinical Research, Insite DME, Novartis, and Vanotech Chengdu.\n\nDr. Moshfeghi was inducted into the 2021 class of the Retina Hall of Fame and\nis a member of the Club Jules Gonin, Retina Society, Macula Society, American\nSociety of Retinal Specialists, and the Association of Pediatric Retinal\nSpecialists.\n\nAbout Ocular Therapeutix, Inc.\nOcular Therapeutix, Inc. is an integrated biopharmaceutical company committed\nto redefining the retina experience. AXPAXLI™ (also known as OTX-TKI),\nOcular’s investigational product candidate for retinal disease, is an\naxitinib intravitreal hydrogel based on its ELUTYX™ proprietary\nbioresorbable hydrogel-based formulation technology. AXPAXLI is currently in\nPhase 3 clinical trials for wet age-related macular degeneration (wet AMD),\nand diabetic retinal disease, including non-proliferative diabetic retinopathy\n(NPDR).\n\nOcular’s pipeline also leverages the ELUTYX technology in its commercial\nproduct DEXTENZA(®), an FDA-approved corticosteroid for the treatment of\nocular inflammation and pain following ophthalmic surgery in adults and\npediatric patients and ocular itching associated with allergic conjunctivitis\nin adults and pediatric patients aged two years or older, and in its\ninvestigational product candidate OTX-TIC, which is a travoprost intracameral\nhydrogel that has completed a Phase 2 clinical trial for the treatment of\nopen-angle glaucoma or ocular hypertension. Ocular is currently evaluating\nnext steps for the OTX-TIC program.\n\nFollow the Company on its website, LinkedIn, or X.\n\nDEXTENZA(®) is a registered trademark of Ocular Therapeutix, Inc. The Ocular\nTherapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are\ntrademarks of Ocular Therapeutix, Inc.\n\nInvestors & Media\nOcular Therapeutix, Inc.\nBill Slattery\nVice President, Investor Relations\nbslattery@ocutx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/20ee0f50-7288-4f81-8546-f2ad2050ddbf)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T11:00:00.409323879Z","server_sent_at_ms":1780398000409},"received_at":"2026-06-02T11:00:00.542Z","source_url":null},"analysis":{"id":"41285","press_release_id":"51854","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from senior leadership and roundtable discussions with prominent retinal disease experts.\n\nThe event will highlight the NDA submission plan for AXPAXLI in wet AMD, updates on the SOL-R and SOL-X trials, and the registrational program for diabetic retinopathy.\n\nA live webcast will be available on the company’s website, with a replay archived for at least 30 days following the presentation.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine Investor Day announcement; wait for the actual presentation deck or transcript for material insights."},"keyFigures":{},"quotedText":"Ocular Therapeutix, Inc. ... will host an Investor Day on Wednesday, June 17, 2026, in New York City.","namedEntities":{"people":[{"name":"Dr. Arshad M. Khanani","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Dr. Lejla Vajzovic","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Dr. Darius M. Moshfeghi","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Bill Slattery","role":"Vice President, Investor Relations"}],"products":["AXPAXLI","OTX-TKI","ELUTYX","DEXTENZA","OTX-TIC","SOL-R","SOL-X"],"companies":[{"name":"Ocular Therapeutix, Inc.","ticker":"OCUL"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a standard announcement of an upcoming Investor Day. While it signals that the company will provide updates on its NDA submission plan and clinical trials, the event itself is a routine corporate communication tool. No new clinical data, regulatory decisions, or financial results are disclosed in this release."},"tickerRelevance":{"others":[],"primary":"OCUL"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"low","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from senior leadership and roundtable discussions with prominent retinal disease experts.\n\nThe event will highlight the NDA submission plan for AXPAXLI in wet AMD, updates on the SOL-R and SOL-X trials, and the registrational program for diabetic retinopathy.\n\nA live webcast will be available on the company’s website, with a replay archived for at least 30 days following the presentation.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Arshad M. Khanani","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Dr. Lejla Vajzovic","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Dr. Darius M. Moshfeghi","role":"Key Opinion Leader / Retinal Disease Expert"},{"name":"Bill Slattery","role":"Vice President, Investor Relations"}],"products":["AXPAXLI","OTX-TKI","ELUTYX","DEXTENZA","OTX-TIC","SOL-R","SOL-X"],"companies":[{"name":"Ocular Therapeutix, Inc.","ticker":"OCUL"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T11:01:55.275Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap","eventGravity":"low","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"durationMs":58018,"modelName":"george-droid-qwen-72b"}}